162 related articles for article (PubMed ID: 16865867)
1. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.
Koo JY; Bagel J; Sweetser MT; Ticho BS
J Drugs Dermatol; 2006; 5(7):623-8. PubMed ID: 16865867
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
4. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
5. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
[TBL] [Abstract][Full Text] [Related]
7. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
8. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.
Legat FJ; Hofer A; Wackernagel A; Salmhofer W; Quehenberger F; Kerl H; Wolf P
Arch Dermatol; 2007 Aug; 143(8):1016-22. PubMed ID: 17709660
[TBL] [Abstract][Full Text] [Related]
9. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
Krell J; Nelson C; Spencer L; Miller S
J Am Acad Dermatol; 2008 Apr; 58(4):609-16. PubMed ID: 18262681
[TBL] [Abstract][Full Text] [Related]
10. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Ellis CN; Krueger GG;
N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
[TBL] [Abstract][Full Text] [Related]
12. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
[TBL] [Abstract][Full Text] [Related]
13. An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
Magliocco MA; Lozano AM; Van Saders C; Schuler KW; Gottlieb AB
J Drugs Dermatol; 2007 Apr; 6(4):424-7. PubMed ID: 17668540
[TBL] [Abstract][Full Text] [Related]
14. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.
van de Kerkhof P; Griffiths CE; Christophers E; Lebwohl M; Krueger GG
Dermatology; 2005; 211(3):256-63. PubMed ID: 16205071
[TBL] [Abstract][Full Text] [Related]
15. Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
[TBL] [Abstract][Full Text] [Related]
16. Alefacept: an expert review concerning the treatment of psoriasis.
Langley RG; Cherman AM; Gupta AK
Expert Opin Pharmacother; 2005 Oct; 6(13):2327-33. PubMed ID: 16218892
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
Bagel J
J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
[TBL] [Abstract][Full Text] [Related]
18. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
[TBL] [Abstract][Full Text] [Related]
19. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
20. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
Ortonne JP; Prinz JC
Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]